Abstract
Introduction: Calcitonin is a polypeptide hormone regulating the metabolism calcium in the body. Many studies showed that calcitonin had analgesic effect on several painful circumstances. The aim of this study was to determine the effects of intranasal calcitonin during the immediate postoperative period on postoperative pain in patients undergoing maxillofacial fracture surgery. Materials and Methods: In this clinical trial which was conducted in April 2019 in Imam Reza Hospital of Tabriz, 16 patients with maxillofacial fracture were divided randomly into two groups. The intervention group was given 200UI of intranasal calcitonin and the control group received nasal spray of NaCl. The severity of pain was then evaluated daily for up to seven days after the operation, with the severity of: no pain (0) to the most severe pain (10) using visual analog scale for pain. The daily dose of analgesic was also measured. The patients were allowed to request 250 mg of injectable acetaminophen each day up to a maximum daily dose of 4 g (maximum permissible dose) in the event of pain. Results: The results show that the pain intensity between two groups was not significantly different. However in the seventh day the total acetaminophen consumption was significantly lower in the intervention group. Conclusion: calcitonin may be a useful medication to help to control the post operative pain by reducing the required dose of routine painkillers.
Highlights
Calcitonin is a polypeptide hormone regulating the metabolism calcium in the body
The aim of this study was to determine the effects of intranasal calcitonin during the immediate postoperative period on postoperative pain in patients undergoing maxillofacial fracture surgery
The results show that the pain intensity between two groups was not significantly different
Summary
Local anesthesia infiltration when combined with general anesthesia (GA) provides good operative condition but has relatively shorter duration of postoperative analgesia. In 1968, calcitonin was isolated from the ultimobranchial glands of the salmon (3), and it was subsequently shown that salmon calcitonin has a relative potency in man that is approximately 20- to 50- fold greater than that of human calcitonin This increased potency is partly due to the greater half-life in circulation compared to human calcitonin, but could be due to higher receptor affinity for the salmon molecule. Calcitonin is the only currently used therapy for the treatment of osteoporosis with the added advantage of relieving bone pain This unique feature provides a further rationale for the clinical use of calcitonin for pain reduction following osteoporotic fractures, as well as other pain syndromes. The aim of this study was to determine the effects of intranasal calcitonin during the immediate postoperative period on postoperative pain in patients undergoing maxillofacial fracture surgery
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
